MDNAF — Medicenna Therapeutics Corp.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1807983 ·
Ontario, Canada
Last close
$0.16
Market Cap
$14.77M
52W High
$1.30
52W Low
$0.16
ADV30
49,770
Next earnings
2027-02-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,451,000 | -5,082,000 | 8,249,000 | 5,691,000 | 6,576,000 |
| Mar 2026 | 0 | — | -5,822,000 | -4,234,000 | 8,454,000 | 6,251,000 | 5,972,000 |
| Dec 2025 | 0 | — | -5,616,000 | -4,364,000 | 13,065,000 | 10,614,000 | 6,853,000 |
| Sep 2025 | 0 | — | -5,470,000 | -4,883,000 | 18,041,000 | 15,748,000 | 7,799,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,807,000
Investing CF
$2,000
Financing CF
$3,819,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-141,743,000
Inventory
—
Receivables
$1,523,000
ST Investments
—
EBIT TTM
$-22,359,000
Pretax Income TTM
$-18,563,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -22,417,000 | -18,409,000 | 8,454,000 | 5,972,000 | 2,482,000 | -17,923,000 |
| Mar 2025 | 0 | -20,406,000 | -11,805,000 | 28,382,000 | 9,287,000 | 19,095,000 | -16,492,000 |
| Mar 2024 | 0 | -18,674,000 | -25,466,000 | 19,134,000 | 13,943,000 | 5,191,000 | -16,260,000 |
| Mar 2023 | 0 | -16,303,000 | -10,048,000 | 36,446,000 | 6,960,000 | 29,486,000 | -12,657,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics, Inc. | $14.73M | $5.65 | — |
| KTTA | Pasithea Therapeutics Corp. | $14.51M | $0.43 | — |
| MCRB | Seres Therapeutics, Inc. | $14.37M | $1.41 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $14.24M | $0.52 | — |
| NCEL | NewcelX Ltd. | $15.48M | $2.68 | — |
News headlines (Yahoo Finance, 1h cache)
Medicenna Therapeutics Reports Second Quarter Fiscal 2027 Financial Results and Provides Corporate Update
2026-11-17 12:45 · Yahoo
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Con
2026-11-16 12:00 · Yahoo
Medicenna Presents ABILITY-1 Data at SITC 2026 Showing 40% ORR in Gastrointestinal Cancer Patients with Biomarker Enriched Tumors Resistant to Approved Therapies
2026-11-09 12:00 · Yahoo
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
2026-11-04 12:00 · Yahoo
Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
2026-10-26 12:52 · Yahoo
Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference
2026-10-22 11:00 · Yahoo
Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026
2026-10-05 13:00 · Yahoo
Medicenna Announces Results of Annual General and Special Meeting of Shareholders
2026-10-01 23:00 · Yahoo
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
2026-09-24 11:00 · Yahoo
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.